Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002045034 | SCV002296668 | uncertain significance | Nephronophthisis 15 | 2021-09-01 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine with arginine at codon 1341 of the CEP164 protein (p.Gly1341Arg). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and arginine. This variant is present in population databases (rs781132728, ExAC 0.02%). This variant has not been reported in the literature in individuals affected with CEP164-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002642146 | SCV003623140 | uncertain significance | Inborn genetic diseases | 2022-05-25 | criteria provided, single submitter | clinical testing | The c.4021G>C (p.G1341R) alteration is located in exon 30 (coding exon 28) of the CEP164 gene. This alteration results from a G to C substitution at nucleotide position 4021, causing the glycine (G) at amino acid position 1341 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |